BACKGROUND: Patients with heart failure (HF) are typically designated as having reduced or preserved ejection fraction (HFREF, HFPEF) because of the importance of left ventricular ejection fraction (LVEF) on therapeutic decisions and prognosis. Such designations are not necessarily static, yet few data exist to describe the natural history of LVEF over time. METHODS AND RESULTS: We identified 2413 patients from Kaiser Permanente Colorado with a primary discharge diagnosis of HF between January 1, 2001, and December 31, 2008, who had ≥2 LVEF measurements separated by ≥30 days. We used multi-state Markov modeling to examine transitions among HFREF, HFPEF, and death. We observed a total of 8183 transitions. Women were more likely than men to transition from HFREF to HFPEF (hazard ratio, 1.85; 95% confidence interval, 1.38-2.47). Patients who were adherent to β-blockers were more likely to transition from HFREF to HFPEF (hazard ratio, 1.53; 95% confidence interval, 1.10-2.13) compared with patients who were nonadherent to β-blockers, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associated with LVEF transitions. Patients who had a previous myocardial infarction were more likely to transition from HFPEF to HFREF (hazard ratio, 1.75; 95% confidence interval, 1.26-2.42). CONCLUSIONS: In this cohort of patients with HF, LVEF is a dynamic factor related to sex, coexisting conditions, and drug therapy. These findings have implications for left ventricular systolic function ascertainment in patients with HF and support evidence-based therapy use, especially β-blockers.
BACKGROUND:Patients with heart failure (HF) are typically designated as having reduced or preserved ejection fraction (HFREF, HFPEF) because of the importance of left ventricular ejection fraction (LVEF) on therapeutic decisions and prognosis. Such designations are not necessarily static, yet few data exist to describe the natural history of LVEF over time. METHODS AND RESULTS: We identified 2413 patients from Kaiser Permanente Colorado with a primary discharge diagnosis of HF between January 1, 2001, and December 31, 2008, who had ≥2 LVEF measurements separated by ≥30 days. We used multi-state Markov modeling to examine transitions among HFREF, HFPEF, and death. We observed a total of 8183 transitions. Women were more likely than men to transition from HFREF to HFPEF (hazard ratio, 1.85; 95% confidence interval, 1.38-2.47). Patients who were adherent to β-blockers were more likely to transition from HFREF to HFPEF (hazard ratio, 1.53; 95% confidence interval, 1.10-2.13) compared with patients who were nonadherent to β-blockers, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associated with LVEF transitions. Patients who had a previous myocardial infarction were more likely to transition from HFPEF to HFREF (hazard ratio, 1.75; 95% confidence interval, 1.26-2.42). CONCLUSIONS: In this cohort of patients with HF, LVEF is a dynamic factor related to sex, coexisting conditions, and drug therapy. These findings have implications for left ventricular systolic function ascertainment in patients with HF and support evidence-based therapy use, especially β-blockers.
Authors: Paul Dubach; Jonathan Myers; Piero Bonetti; Thomas Schertler; Victor Froelicher; Doris Wagner; Markus Scheidegger; Matthias Stuber; Roger Luchinger; Juerg Schwitter; Otto Hess Journal: Am Heart J Date: 2002-04 Impact factor: 4.749
Authors: M Packer; A J Coats; M B Fowler; H A Katus; H Krum; P Mohacsi; J L Rouleau; M Tendera; A Castaigne; E B Roecker; M K Schultz; D L DeMets Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: Frederick A Masoudi; Edward P Havranek; Grace Smith; Ronald H Fish; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2003-01-15 Impact factor: 24.094
Authors: M A Konstam; M W Kronenberg; M F Rousseau; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan Journal: Circulation Date: 1993-11 Impact factor: 29.690
Authors: Frederick A Masoudi; Edward P Havranek; Pam Wolfe; Cary P Gross; Saif S Rathore; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2003-08 Impact factor: 4.749
Authors: A Hjalmarson; S Goldstein; B Fagerberg; H Wedel; F Waagstein; J Kjekshus; J Wikstrand; D El Allaf; J Vítovec; J Aldershvile; M Halinen; R Dietz; K L Neuhaus; A Jánosi; G Thorgeirsson; P H Dunselman; L Gullestad; J Kuch; J Herlitz; P Rickenbacher; S Ball; S Gottlieb; P Deedwania Journal: JAMA Date: 2000-03-08 Impact factor: 56.272
Authors: Nuria Farré; Josep Lupon; Eulàlia Roig; Jose Gonzalez-Costello; Joan Vila; Silvia Perez; Marta de Antonio; Eduard Solé-González; Cristina Sánchez-Enrique; Pedro Moliner; Sonia Ruiz; C Enjuanes; Sonia Mirabet; Antoni Bayés-Genís; Josep Comin-Colet Journal: BMJ Open Date: 2017-12-21 Impact factor: 2.692
Authors: Adovich S Rivera; Arjun Sinha; Faraz S Ahmad; Edward Thorp; Jane E Wilcox; Donald M Lloyd-Jones; Matthew J Feinstein Journal: Circ Heart Fail Date: 2021-08-10 Impact factor: 10.447